Drug intelligence / Profile preview

VXA-BYW-10

Development stage: Phase 1
Lead developer: Vaxart
Modality: Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Oral

Overview

VXA-BYW-10 is an orally administered, adenoviral vector-based vaccine developed for the prophylaxis of influenza B virus infection. It is designed to stimulate the immune system by acting as a TLR3 (Toll-like receptor 3) agonist, thereby enhancing immune responses against influenza B. The vaccine was developed by Vaxart and has been evaluated in phase 1 clinical trials to assess its safety and immunogenicity in healthy adults[1][2][4][7].

Other names: Influenza B Oral Vaccine

Targets

TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on VXA-BYW-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VXA-BYW-10.

Explore the full profile